Viridian Therapeutics Inc

VRDN remains in a Stage 2 advancing regime within the broader uptrend, but near-term price is extended above rising EMAs with extreme overbought readings. Medium-term structure stays bullish with a clear HH/HL sequence intact, yet execution is deferred—awaiting a shallow pullback into the 9/21 EMA support zone for disciplined entry.

• ↑FDA approved Lumvoa for active & chronic TED in $4B+ market
• ↑VRDN001 delivered 75% proptosis response rate in pivotal trials
• ↓Persistent losses and weak profitability raise sustainability concerns